重组人血管内皮抑制素（恩度）联合改良的FOLFOX7方案治疗晚期结直肠癌的临床观察.docVIP

精品论文 参考文献 重组人血管内皮抑制素（恩度）联合改良的FOLFOX7方案治疗晚期结直肠癌的临床观察 马楠1 徐蓉2 （1新疆维吾尔自治区人民医院乳腺、甲状腺外一科 新疆乌鲁木齐 830000） （2新疆维吾尔自治区人民医院肿瘤科 新疆乌鲁木齐 830000） 【摘要】目的 观察重组人血管内皮抑制素（恩度）联合改良的FOLFOX7方案治疗晚期结直肠癌的疗效和安全性。方法　22例晚期结直肠癌患者均接受化疗: 重组人血管内皮抑制素 15ml d1-5，奥沙利铂100 mg /m2 (2h 静脉滴注)，d1，5-氟尿嘧400mg／m2 (静脉泵泵入46h)＋亚叶酸钙400mg／m2（2h 静脉滴注），14d为1个周期,重复使用2个周期为1个疗程。2个疗程后评价疗效及毒副反应。结果　CR 0例，PR 12例，SD 7例，PD 3例，总有效率为54.5%，临床获益率为86.4%。主要毒副反应为周围神经毒性、胃肠道反应、骨髓抑制。结论 重组人血管内皮抑制素（恩度）联合改良的FOLFOX7方案治疗晚期结直肠癌毒副反应患者多可耐受，疗效较好。 【关键词】血管内皮抑制素 改良的FOLFOX7方案 晚期结直肠癌 【中图分类号】R730.5 【文献标识码】A 【文章编号】2095-1752（2013）26-0145-02 Clinic Study of Recombinant Human Endostatin Factors (endostatin) Combined with the Modified FOLFOX7 Regiment in Advanced Colorectal Cancer Ma Nan1, Xu Rong2 (The Peoples Hospital of Xinjiang, 1 Department of Galactophore and Thyroid, 2 Department of Medical Oncology,Urumqi 830000) 【Abstract】 Objective: To evaluate the efficacy and safety of recombinant human vascular endothelial inhibin (TU) combined with the modified FOLFOX7 regiment for treatment of advanced g colorectal cancer. Methods: 22 patients with advanced colorectal cancer received chemotherapy: recombinant human endostatin prime 15ml d1-5, oxaliplatin 100 mg / m 2 (2h intravenous infusion), d1, 5 - Fu Niaomi 400mg/m2 (intravenous infusion pump into 46h) + calcium folinate 400mg/m2 (2h intravenous infusion), 14d as a cycle, repeated use of two cycles for a course of treatment. Evaluated the efficacy and toxicity after two courses. Results: CR 0 case, PR 12 cases, SD 7 cases, PD 3 cases, the total effective rate was 54.5%, clinical benefit rate was 86.4%. The major toxicities were peripheral neurotoxicity, gastrointestinal tract, bone marrow suppression. Conclusion: The recombinant human vascular endothelial inhibin (TU) combined with modified FOLFOX7 regiment was more effective and relatively safe for the treatment of advanced colorectal cancer. 【Key words】 endostatin factors modified